Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
Academic Article
Publication Date:
2020
Short description:
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis / Danese, S., Neurath, M.F., Kopoń, A., Zakko, S.F., Simmons, T.C., Fogel, R., Siegel, C.A., Panaccione, R., Zhan, X., Usiskin, K., Chitkara, D.. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - 18:11(2020), pp. 2526-2534.e9-2534.e9. [10.1016/j.cgh.2019.12.032]
abstract:
New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy.
Iris type:
1.1 Articolo in rivista
Keywords:
Biologic-Naïve; CRP; IBD; TMS
List of contributors:
Danese, Silvio; Neurath, Markus F; Kopoń, Adam; Zakko, Salam F; Simmons, Timothy C; Fogel, Ronald; Siegel, Corey A; Panaccione, Remo; Zhan, Xiaojiang; Usiskin, Keith; Chitkara, Denesh
Published in: